Recently, the 36 Krypton Venture Capital Research Institute published the list of “2023 Science and Technology Entrepreneurs”. Dr. Ke Xu, co-founder and CEO of Shenzhen Moyuan Biotechnology Co., Ltd (META Pharmaceuticals), has been recognized as an exceptional entrepreneur in the biomedical research field and was included in the “2023 Science and Technology Entrepreneurs” list.

The “2023 Science Entrepreneurs” represents the inaugural survey conducted by the 36Krypton Venture Capital Research Institute in collaboration with its latest summit IP – Waves. This survey is centered around the phenomenon of scientists’ entrepreneurship. It meticulously identifies nearly 100 science entrepreneurs who have achieved remarkable success in the “research + entrepreneurship” model across various domains, including cutting-edge technology, advanced manufacturing, intelligent hardware, new energy, biotechnology, healthcare, and local lifestyle.These exceptional individuals have been carefully selected for their significant contributions to the intersection of research and business.

This award acknowledges Dr. Ke Xu’s remarkable accomplishments and entrepreneurial prowess in the field of bio-immune metabolism, as recognized by both the industry and the media. It also signifies a strong vote of confidence in META Pharmaceuticals’ future trajectory. To quote Waves, when it comes to navigating the delicate balance between scientific research and entrepreneurship, “there are very few individuals who possess the capacity to comprehend both modes of thinking and effectively harmonize them.

Dr. Ke Xu, the Founder of META Pharmaceuticals (Source: Weill Cornell Medical College), holds degrees from McMaster University and Columbia University. In 2013, he joined the Immunology and Microbial Pathogenesis (IMP) Program at Weill Cornell Medical College. Over the course of more than a decade of basic biological research, Dr. Xu has focused on the intricate relationship between the immune system and metabolism. His work has demonstrated the pivotal role of nutrient metabolism in regulating immune responses at the molecular and cellular levels.

Currently, Dr. Ke Xu serves as the co-founder of Shenzhen Moyuan Biotechnology Co., Ltd (META Pharmaceuticals). Alongside his founding team, he dedicates efforts to modulating immune system function by regulating immune cell metabolism. Their mission is to improve and treat a wide range of conditions arising from immune and metabolic system disorders, including autoimmune disorders, cancer, metabolic disorders, and age-related chronic diseases.